دورية أكاديمية
أعرض في EDS

Correlation of Matrisome-Associatted Gene Expressions with LOX Family Members in Astrocytomas Stratified by IDH Mutation Status.

التفاصيل البيبلوغرافية
العنوان: Correlation of Matrisome-Associatted Gene Expressions with LOX Family Members in Astrocytomas Stratified by IDH Mutation Status.
المؤلفون: Laurentino TS; Cellular and Molecular Biology Laboratory (LIM 15), Neurology Department, Faculdade de Medicina (FMUSP), Universidade de Sao Paulo, Sao Paulo 01246-903, SP, Brazil., Soares RDS; Cellular and Molecular Biology Laboratory (LIM 15), Neurology Department, Faculdade de Medicina (FMUSP), Universidade de Sao Paulo, Sao Paulo 01246-903, SP, Brazil., Marie SKN; Cellular and Molecular Biology Laboratory (LIM 15), Neurology Department, Faculdade de Medicina (FMUSP), Universidade de Sao Paulo, Sao Paulo 01246-903, SP, Brazil., Oba-Shinjo SM; Cellular and Molecular Biology Laboratory (LIM 15), Neurology Department, Faculdade de Medicina (FMUSP), Universidade de Sao Paulo, Sao Paulo 01246-903, SP, Brazil.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2022 Aug 23; Vol. 23 (17). Date of Electronic Publication: 2022 Aug 23.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Astrocytoma*/genetics , Brain Neoplasms*/metabolism , Extracellular Matrix*/metabolism , Extracellular Matrix Proteins*/genetics , Glioblastoma*/genetics , Glioma*/metabolism, Amino Acid Oxidoreductases/genetics ; Amino Acid Oxidoreductases/metabolism ; Collagen/metabolism ; Gene Expression ; Humans ; Isocitrate Dehydrogenase/genetics ; Mutation
مستخلص: Tumor cell infiltrative ability into surrounding brain tissue is a characteristic of diffusely infiltrative astrocytoma and is strongly associated with extracellular matrix (ECM) stiffness. Collagens are the most abundant ECM scaffolding proteins and contribute to matrix organization and stiffness. LOX family members, copper-dependent amine oxidases, participate in the collagen and elastin crosslinking that determine ECM tensile strength. Common IDH mutations in lower-grade gliomas (LGG) impact prognosis and have been associated with ECM stiffness. We analyzed the expression levels of LOX family members and matrisome-associated genes in astrocytoma stratified by malignancy grade and IDH mutation status. A progressive increase in expression of all five LOX family members according to malignancy grade was found. LOX , LOXL1 , and LOXL3 expression correlated with matrisome gene expressions. LOXL1 correlations were detected in LGG with IDH mutation (IDH mut ), LOXL3 correlations in LGG with IDH wild type (IDH wt ) and strong LOX correlations in glioblastoma (GBM) were found. These increasing correlations may explain the increment of ECM stiffness and tumor aggressiveness from LGG-IDH mut and LGG-IDH wt through to GBM. The expression of the mechanosensitive transcription factor, β-catenin, also increased with malignancy grade and was correlated with LOXL1 and LOXL3 expression, suggesting involvement of this factor in the outside-in signaling pathway.
References: Prog Nucleic Acid Res Mol Biol. 2001;70:1-32. (PMID: 11642359)
Int J Cancer. 2017 Sep 1;141(5):998-1010. (PMID: 28542982)
Genes Dev. 2012 Sep 15;26(18):2038-49. (PMID: 22925884)
Cancer Metastasis Rev. 2009 Jun;28(1-2):113-27. (PMID: 19153673)
Nat Rev Cancer. 2011 Aug 11;11(9):671-7. (PMID: 21833026)
Cell Struct Funct. 2012;37(1):75-80. (PMID: 22453058)
Oncotarget. 2015 Aug 28;6(25):20885-901. (PMID: 26369702)
Cell. 2009 Nov 25;139(5):891-906. (PMID: 19931152)
Exp Mol Med. 2019 Feb 21;51(2):1-12. (PMID: 30804321)
Cancer Lett. 2018 Mar 28;417:174-181. (PMID: 29309816)
Nat Med. 2014 Apr;20(4):332-3. (PMID: 24710372)
Cell Death Differ. 2018 May;25(5):935-950. (PMID: 29229995)
Front Mol Biosci. 2020 Jan 31;6:160. (PMID: 32118030)
J Biol Chem. 2019 Feb 8;294(6):2133-2141. (PMID: 30541925)
Cells. 2019 Oct 31;8(11):. (PMID: 31683669)
Biochem Biophys Res Commun. 2018 Jun 27;501(3):619-627. (PMID: 29729273)
Front Oncol. 2020 Oct 02;10:576701. (PMID: 33134175)
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18892-7. (PMID: 20956321)
J Endocrinol. 1994 Sep;142(3):571-9. (PMID: 7525827)
Cancer Biother Radiopharm. 2012 Dec;27(10):672-7. (PMID: 23140307)
J Biol Chem. 2000 Apr 14;275(15):11026-33. (PMID: 10753905)
J Neurooncol. 2018 Apr;137(2):395-407. (PMID: 29294230)
Cell Mol Life Sci. 2006 Oct;63(19-20):2304-16. (PMID: 16909208)
Mol Cell Biochem. 2017 Nov;435(1-2):197-206. (PMID: 28526934)
J Neurooncol. 2014 May;118(1):39-47. (PMID: 24595468)
Epigenetics Chromatin. 2016 Jul 27;9:32. (PMID: 27468311)
Int J Mol Sci. 2022 Apr 19;23(9):. (PMID: 35562862)
Oncotarget. 2017 Jul 25;8(30):49165-49177. (PMID: 28467784)
Physiol Res. 2007;56 Suppl 1:S51-S60. (PMID: 17552894)
Oncol Lett. 2011 Sep 1;2(5):831-838. (PMID: 22866136)
Cancer Cell. 2009 Jan 6;15(1):35-44. (PMID: 19111879)
Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16369-74. (PMID: 21911388)
Development. 2014 Aug;141(16):3233-42. (PMID: 25063458)
Semin Oncol. 2019 Jun;46(3):284-290. (PMID: 31488338)
Cancer Immunol Immunother. 2020 Feb;69(2):223-235. (PMID: 31650200)
Oncol Lett. 2018 Feb;15(2):2431-2440. (PMID: 29434955)
Cell Physiol Biochem. 2018;49(3):1097-1109. (PMID: 30196284)
EMBO J. 2005 Oct 5;24(19):3446-58. (PMID: 16096638)
Methods Enzymol. 2011;499:167-82. (PMID: 21683254)
Semin Cancer Biol. 2018 Dec;53:168-177. (PMID: 30063965)
Int J Oncol. 2019 May;54(5):1676-1690. (PMID: 30816490)
Nat Rev Cancer. 2012 Jul 19;12(8):540-52. (PMID: 22810810)
Cancers (Basel). 2019 May 22;11(5):. (PMID: 31121900)
Cancer Lett. 2019 May 1;449:207-214. (PMID: 30796968)
Cancer Res. 2002 Aug 1;62(15):4478-83. (PMID: 12154058)
Cell Rep. 2015 Jan 20;10(3):398-413. (PMID: 25600874)
J Microsc. 2017 Feb;265(2):207-213. (PMID: 27643398)
Mol Biol Cell. 2018 Oct 1;29(20):2378-2385. (PMID: 30091653)
Biochem Soc Trans. 2020 Jun 30;48(3):1187-1198. (PMID: 32412078)
J Clin Med. 2020 Dec 28;10(1):. (PMID: 33379277)
Invest Ophthalmol Vis Sci. 2011 Jul 15;52(8):5240-50. (PMID: 21546528)
Oncotarget. 2016 May 31;7(22):32100-12. (PMID: 27050073)
Nat Genet. 2013 Jun;45(6):580-5. (PMID: 23715323)
Nature. 2010 Jun 17;465(7300):966. (PMID: 20559394)
Cancers (Basel). 2022 Feb 18;14(4):. (PMID: 35205794)
J Proteome Res. 2014 Dec 5;13(12):5660-9. (PMID: 25325876)
Genome Biol. 2010;11(10):R106. (PMID: 20979621)
Cell. 2013 Oct 10;155(2):462-77. (PMID: 24120142)
Front Cell Dev Biol. 2020 Oct 22;8:580464. (PMID: 33195221)
J Proteome Res. 2021 Oct 1;20(10):4693-4707. (PMID: 34533964)
Int J Mol Sci. 2016 Dec 29;18(1):. (PMID: 28036074)
Front Oncol. 2020 Feb 21;10:183. (PMID: 32154177)
Cancers (Basel). 2020 Jan 29;12(2):. (PMID: 32013066)
Int J Clin Exp Pathol. 2018 Apr 01;11(4):2032-2037. (PMID: 31938310)
J Drug Target. 2019 Aug;27(7):790-796. (PMID: 30457362)
J Cell Mol Med. 2011 May;15(5):1013-31. (PMID: 21155971)
Nat Commun. 2020 Oct 9;11(1):5120. (PMID: 33037194)
Front Cell Dev Biol. 2018 Jun 28;6:66. (PMID: 30003082)
Sci Rep. 2015 May 29;5:10568. (PMID: 26024311)
Mol Cell. 2017 Jan 19;65(2):296-309. (PMID: 28065600)
J Cell Biochem. 2007 Aug 15;101(6):1338-54. (PMID: 17471532)
Tumour Biol. 2017 Mar;39(3):1010428317692227. (PMID: 28347245)
Cancer Cell. 2011 Jan 18;19(1):17-30. (PMID: 21251613)
Nat Cell Biol. 2016 Dec;18(12):1336-1345. (PMID: 27820599)
Genomics. 1992 May;13(1):62-9. (PMID: 1577494)
Cell Physiol Biochem. 2018;48(3):1382-1396. (PMID: 30048971)
FASEB J. 2018 Jan;32(1):143-154. (PMID: 28904019)
Oncogene. 2022 Apr;41(17):2458-2469. (PMID: 35292774)
Cells. 2019 Mar 20;8(3):. (PMID: 30897858)
Essays Biochem. 2019 Sep 13;63(3):349-364. (PMID: 31488698)
Mol Cell. 2015 Nov 19;60(4):661-75. (PMID: 26585387)
Front Cell Neurosci. 2022 Feb 18;16:838548. (PMID: 35250490)
Aging (Albany NY). 2021 Feb 1;13(4):5284-5296. (PMID: 33535177)
PLoS One. 2015 Mar 19;10(3):e0119781. (PMID: 25790191)
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. (PMID: 34185076)
Science. 2009 Apr 10;324(5924):261-5. (PMID: 19359588)
Genet Test Mol Biomarkers. 2021 May;25(5):334-345. (PMID: 33970702)
Cancer Metab. 2021 Apr 28;9(1):18. (PMID: 33910646)
Cancer Res. 2006 May 15;66(10):5216-23. (PMID: 16707446)
Nat Cell Biol. 2002 Apr;4(4):E83-90. (PMID: 11944041)
Matrix Biol. 2016 Jan;49:10-24. (PMID: 26163349)
Sci Rep. 2022 Mar 11;12(1):4295. (PMID: 35277559)
FASEB J. 2018 Aug;32(8):4459-4469. (PMID: 29547702)
Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210)
Head Neck. 2013 Feb;35(2):250-6. (PMID: 22367676)
Int J Cancer. 2008 Feb 15;122(4):807-15. (PMID: 17960622)
Nat Commun. 2020 May 15;11(1):2416. (PMID: 32415208)
Nat Med. 2011 Mar;17(3):291-3. (PMID: 21383741)
N Engl J Med. 2009 Feb 19;360(8):765-73. (PMID: 19228619)
Cancers (Basel). 2019 May 26;11(5):. (PMID: 31130685)
Int J Mol Sci. 2021 Jul 28;22(15):. (PMID: 34360836)
Anat Rec. 2002 Nov 1;268(3):302-16. (PMID: 12382326)
Bone Rep. 2021 Apr 13;14:101063. (PMID: 33981809)
BMC Cancer. 2014 Jul 22;14:532. (PMID: 25052686)
Neuropathology. 2014 Aug;34(4):343-52. (PMID: 24612214)
Int J Mol Sci. 2021 Sep 14;22(18):. (PMID: 34576068)
Exp Cell Res. 2017 Mar 1;352(1):157-163. (PMID: 28189640)
Amino Acids. 2008 Nov;35(4):703-10. (PMID: 18431533)
Oncol Rep. 2014 Feb;31(2):940-6. (PMID: 24337203)
Neurol Sci. 2014 Jun;35(6):839-45. (PMID: 24362902)
Nat Rev Cancer. 2014 Jun;14(6):430-9. (PMID: 24827502)
Genet Mol Res. 2008 Apr 22;7(2):371-8. (PMID: 18551403)
J Biol Chem. 2012 Sep 21;287(39):32367-80. (PMID: 22791710)
معلومات مُعتمدة: #2015/03614-5 São Paulo Research Foundation; #2016/05777-1 São Paulo Research Foundation; #2020/02988-9 São Paulo Research Foundation; #2021/01207-4 São Paulo Research Foundation
فهرسة مساهمة: Keywords: LOX; LOXL1; LOXL3; diffuse astrocytic; extracellular matrix; glioblastoma; lysyl oxidase; matrisome; progression
المشرفين على المادة: 0 (Extracellular Matrix Proteins)
9007-34-5 (Collagen)
EC 1.1.1.41 (Isocitrate Dehydrogenase)
EC 1.4.- (Amino Acid Oxidoreductases)
EC 1.4.3.- (LOXL1 protein, human)
EC 1.4.3.- (LOXL3 protein, human)
تواريخ الأحداث: Date Created: 20220909 Date Completed: 20220912 Latest Revision: 20220930
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9455728
DOI: 10.3390/ijms23179507
PMID: 36076905
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms23179507